Article PDF first page preview

First page of Sequential Amnioinfusion Protocol for Treating Fetal Renal Failure: Impact on Survival and Transition to Renal Transplantation

Fetal renal failure (FRF) is a challenging antenatal diagnosis associated with insufficient pulmonary development and potential compromise for the future possibility of dialysis and kidney transplantation. Even in cases in which lung development can be fostered by serial amnioinfusions, infants who are born prematurely may not qualify for peritoneal dialysis due to weight criteria. We describe our outcomes after introducing an integrated approach at two institutions to prenatal management of FRF with a serial amnioinfusion (AI) protocol and postnatal management with peritoneal dialysis. Our primary endpoint was survival to 6 months of age with successful dialysis, and the secondary outcomes included the ability to transition to renal transplantation. The mean gestational age at which AIs were initiated was 23.3 + 2.32 weeks for the whole cohort. There was no significant difference between survivors (22.51 + 1.70 weeks) and non-survivors (23.31 + 2.69, p=0.339) in the gestational age at initiation of AIs. The mean gestational age at delivery for the entire cohort was 34.8 + 2.62 weeks, and there was a trend toward but did not achieve significance between survivors (35.0 + 1.60 weeks) compared to non-survivors (33.17 + 3.34 weeks, p=0.066). Survival to delivery was 100% for the total AI cohort (n=30). 83% of patients alive at 48 hours survived the neonatal period and of those surviving the neonatal period, 62.5% survived a minimum of 6 months on outpatient peritoneal dialysis (PD). This series also established that PD can be successfully performed in neonates as small as 1500g. Three patients have successfully undergone renal transplantation. Serial AIs for fetal renal failure offer the potential, not only in neonatal pulmonary survival but also long-term survival to kidney transplantation.

Journal Section:
Fetal Therapy
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.